Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo

Heart Rhythm

Volumn 9, Issue 10, 2012, Pages 1718-1726

  Varkevisser, Rosanne ^a   Wijers, Sofieke C ^a   Van Der Heyden, Marcel A G ^a   Beekman, Jet D M ^a   Meine, Mathias ^a   Vos, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biomarkers; Chronic AV block dog; Drugs; Long QT syndrome; Repolarization; Short term variability; Torsades de pointes

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; AMLODIPINE; AZITHROMYCIN; BEPRIDIL; CANDESARTAN; CILNIDIPINE; FLUNARIZINE; ION CHANNEL; LIDOCAINE; MOXIFLOXACIN; RANOLAZINE; SOTALOL; TERFENADINE; VERAPAMIL;

BEAT TO BEAT VARIABILITY OF REPOLARIZATION; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DISEASE COURSE; ELECTROCARDIOGRAM; GENE MUTATION; HEART BEAT; HEART PROARRHYTHMIA; HEART REPOLARIZATION; INCIDENCE; LONG QT SYNDROME; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; T WAVE; TORSADE DES POINTES;

EID: 84866737323     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.05.016     Document Type: Article

References (63)

1. W. Haverkamp, G. Breithardt, A.J. Camm The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology Cardiovasc Res 47 2000 219 233
2. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability Notice Fed Regist 70 2005 61134 61135
3. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability Notice Fed Reg 70 2005 61133 61134
4. M.B. Thomsen, J. Matz, P.G. Volders, M.A. Vos Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias Pharmacol Therapeut 112 2006 150 170
5. M.B. Thomsen, S.C. Verduyn, M. Stengl Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs Circulation 110 2004 2453 2459
6. M. Brennan, M. Palaniswami, P. Kamen Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability? IEEE Trans Biomed Eng 48 2001 1342 1347
7. W. Shimizu, M. Horie Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels Circ Res 109 2011 97 109
8. C.L. Anderson, B.P. Delisle, B.D. Anson Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism Circulation 113 2006 365 373
9. W.S. Redfern, L. Carlsson, A.S. Davis Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc Res 58 2003 32 45
10. R.R. Fenichel, M. Malik, C. Antzelevitch Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 2004 475 495
11. D.M. Roden Acquired long QT syndromes and the risk of proarrhythmia J Cardiovasc Electrophysiol 11 2000 938 940
12. L. Belardinelli, C. Antzelevitch, M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol Sci 24 2003 619 625
13. A. Oros, M.J. Houtman, P. Neco Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action Br J Pharmacol 161 2010 162 175
14. G. Antoons, A. Oros, J.D. Beekman Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model J Am Coll Cardiol 55 2010 801 809
15. M.B. Thomsen, P.G. Volders, J.D. Beekman, J. Matz, M.A. Vos Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes J Am Coll Cardiol 48 2006 1268 1276
16. T.D. Gbadebo, R.W. Trimble, M.S. Khoo, J. Temple, D.M. Roden, M.E. Anderson Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes Circulation 105 2002 770 774
17. N.J. Bokil, J.M. Baisden, D.J. Radford, K.M. Summers Molecular genetics of long QT syndrome Mol Genet Metab 101 2010 1 8
18. N. Hofman, A.A. Wilde, S. Kaab Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? Eur Heart J 28 2007 575 580
19. R. Bai, C. Napolitano, R. Bloise, N. Monteforte, S.G. Priori Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing Circ Arrhythm Electrophysiol 2 2009 6 15
20. G. Gintant An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation Pharmacol Therapeut 129 2011 109 119
21. R.L. Martin, J.S. McDermott, H.J. Salmen, J. Palmatier, B.F. Cox, G.A. Gintant The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block J Cardiovasc Pharmacol 43 2004 369 379
22. S. Viskin The QT interval: too long, too short or just right Heart Rhythm 6 2009 711 715
23. S. Viskin, U. Rosovski, A.J. Sands Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one Heart Rhythm 2 2005 569 574
24. P.G. Postema, J.S. De Jong, I.A. Van der Bilt, A.A. Wilde Accurate electrocardiographic assessment of the QT interval: teach the tangent Heart Rhythm 5 2008 1015 1018
25. N.W. Taggart, C.M. Haglund, D.J. Tester, M.J. Ackerman Diagnostic miscues in congenital long-QT syndrome Circulation 115 2007 2613 2620
26. D.M. Roden Taking the "idio" out of "idiosyncratic": predicting torsades de pointes Pacing Clin Electrophysiol 21 1998 1029 1034
27. R.L. Verrier, T. Klingenheben, M. Malik Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility - consensus guideline by International Society for Holter and Noninvasive Electrocardiology J Am Coll Cardiol 58 2011 1309 1324
28. R.D. Berger, E.K. Kasper, K.L. Baughman, E. Marban, H. Calkins, G.F. Tomaselli Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy Circulation 96 1997 1557 1565
29. L.M. Hondeghem, H.R. Lu, K. van Rossem, F. De Clerck Detection of proarrhythmia in the female rabbit heart: blinded validation J Cardiovasc Electrophysiol 14 2003 287 294
30. A. Oros, J.D. Beekman, M.A. Vos The canine model with chronic, complete atrio-ventricular block Pharmacol Ther 119 2008 168 178
31. M.A. Vos, S.H. de Groot, S.C. Verduyn Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling Circulation 98 1998 1125 1135
32. 2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart Br J Pharmacol 158 2009 1366 1374
33. A. Oros, P.G. Volders, J.D. Beekman, T. van der Nagel, M.A. Vos Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block Heart Rhythm 3 2006 1339 1345
34. M.B. Thomsen, J.D. Beekman, N.J. Attevelt No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block Br J Pharmacol 149 2006 1039 1048
35. A. Takahara, Y. Nakamura, A. Sugiyama Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone Eur J Pharmacol 596 2008 127 131
36. K. Chiba, A. Sugiyama, T. Hagiwara, S. Takahashi, K. Takasuna, K. Hashimoto In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome Eur J Pharmacol 486 2004 189 200
37. J. Schneider, R. Hauser, J.O. Andreas, K. Linz, U. Jahnel Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs Eur J Pharmacol 512 2005 53 60
38. E. Detre, M.B. Thomsen, J.D. Beekman, K.U. Petersen, M.A. Vos Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes Br J Pharmacol 145 2005 397 404
39. A. Takahara, A. Sugiyama, Y. Ishida Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias Br J Pharmacol 147 2006 634 641
40. D.J. Gallacher, A. Van de Water, H. van der Linde In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome Cardiovasc Res 76 2007 247 256
41. H. van der Linde, A. Van de Water, W. Loots A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs J Pharmacol Toxicol Methods 52 2005 168 177
42. C. Lengyel, A. Varro, K. Tabori, J.G. Papp, I. Baczko Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes Br J Pharmacol 151 2007 941 951
43. T. Vormberge, M. Hoffmann, H. Himmel Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve J Pharmacol Toxicol Methods 54 2006 130 140
44. M.B. Thomsen, M. Truin, J.M. van Opstal Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization Basic Res Cardiol 100 2005 279 287
45. J.M. van Opstal, M. Schoenmakers, S.C. Verduyn Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome Circulation 104 2001 2722 2727
46. M.B. Thomsen, A. Oros, M. Schoenmakers Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation Cardiovasc Res 73 2007 521 530
47. L. Carlsson, B. Andersson, G. Linhardt, L. Lofberg Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo J Cardiovasc Pharmacol 54 2009 82 89
48. I. Jacobson, L. Carlsson, G. Duker Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit J Pharmacol Toxicol Methods 63 2011 40 46
49. L. Nalos, R. Varkevisser, M. Jonsson Comparison of I(Kr) blocking drugs moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals insufficient specificity of isolated cardiomyocytes Br J Pharmacol 165 2012 467 478
50. A. Farkas, J. Dempster, S.J. Coker Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model Br J Pharmacol 154 2008 958 970
51. A.S. Farkas, L. Rudas, P. Makra Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in alpha(1)-adrenoceptor-stimulated, anaesthetized rabbits Br J Pharmacol 161 2010 1477 1495
52. D. Vincze, A.S. Farkas, L. Rudas Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits Br J Pharmacol 153 2008 75 89
53. P. Oosterhoff, A. Oros, M.A. Vos Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs Anadolu Kardiyol Derg 7 2007 73 78
54. S.K. Winckels, M.B. Thomsen, P. Oosterhoff High-septal pacing reduces ventricular electrical remodeling and proarrhythmia in chronic atrioventricular block dogs J Am Coll Cardiol 50 2007 906 913
55. P. Oosterhoff, M.B. Thomsen, J.N. Maas High-rate pacing reduces variability of repolarization and prevents repolarization-dependent arrhythmias in dogs with chronic AV block J Cardiovasc Electrophysiol 21 2010 1384 1391
56. A. Dunnink, S. Sharif, P. Oosterhoff Anesthesia and arrhythmogenesis in the chronic atrioventricular block dog model J Cardiovasc Pharmacol 55 2010 601 608
57. M. Hinterseer, M.B. Thomsen, B.M. Beckmann Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study Eur Heart J 29 2008 185 190
58. M. Hinterseer, B.M. Beckmann, M.B. Thomsen Relation of increased short-term variability of QT interval to congenital long-QT syndrome Am J Cardiol 103 2009 1244 1248
59. H.J. Ritsema van Eck, F.J. Broeyer, G. van Herpen, J. Burggraaf, J.A. Kors Short-term QT variability: a marker for reduced repolarization reserve in anthracyclin therapy Comput Cardiol 36 2009 585 588
60. M. Hinterseer, B.M. Beckmann, M.B. Thomsen Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure Am J Cardiol 106 2010 216 220
61. C. Lengyel, A. Orosz, P. Hegyi Increased short-term variability of the QT interval in professional soccer players: possible implications for arrhythmia prediction PLoS One 6 2011 e18751
62. P. Oosterhoff, L.G. Tereshchenko, M.A. van der Heyden Short-term variability of repolarization predicts ventricular tachycardia and sudden cardiac death in patients with structural heart disease: a comparison to QT variability index Heart Rhythm 8 2011 1584 1590
63. J. Seegers, M.A. Vos, P. Flevari Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype Europace 14 2012 416 422